The rapid rise of hemp-derived cannabinoids (HDCs) has created a new space in cannabinoid research and commerce, offering new therapeutic potentials and market opportunities and controversies. This fast-growing sector also faces critical challenges, including significant gaps in state and federal regulations and the presence of irresponsible actors exploiting legal loopholes. These issues raise concerns about consumer safety, product integrity, and the long-term viability of the industry.

This panel unites scientists, policymakers, and legal professionals to provide a comprehensive exploration of the HDC landscape, emphasizing both its promise and its pitfalls. Attendees will learn about the latest research on the pharmacology and therapeutic potential of HDCs, alongside a frank discussion of the risks posed by unregulated products, misleading marketing practices, and inconsistent quality standards.